UBS analyst Mark Yokoyama initiated coverage of SanBio (SNBIF) with a Neutral rating and 2,000 yen price target The company’s platform expansion offers long term upside but limited near term vaIue, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNBIF: